Persistent donor derived Vδ4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI

Oncotarget

Volumn 7, Issue 28, 2016, Pages 42943-42952

  Xu, Ling ^a   Weng, Jianyu ^b   Huang, Xin ^b   Zeng, Chengwu ^a   Chen, Shaohua ^a   Geng, Suxia ^b   Yang, Lijian ^a   Wu, Suijing ^b   Huang, Suming ^c   Du, Xin ^b   Li, Yangqiu ^a  

^a JINAN UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Allo HSCT; DLI; Immune response; Immunity; Immunology and Microbiology Section; MRD; T cell repertoire; T ALL

Indexed keywords

GAMMA INTERFERON; METHOTREXATE; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; LEUKEMIA RELAPSE; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; OVERALL SURVIVAL; T CELL LEUKEMIA; T LYMPHOCYTE; V DELTA 4 T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; BLOOD DONOR; CELL CLONE; GENE EXPRESSION; GENETICS; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; LYMPHOCYTE TRANSFUSION; METABOLISM; PROCEDURES; SURVIVAL ANALYSIS; TRANSPLANTATION; TREATMENT OUTCOME; TUMOR RECURRENCE;

BLOOD DONORS; CLONE CELLS; GENE EXPRESSION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE TRANSFUSION; NEOPLASM RECURRENCE, LOCAL; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84978765453     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10260     Document Type: Article

References (41)

1. Roti G and Stegmaier K. New Approaches to Target T-ALL. Front Oncol. 2014; 4:170
2. Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, Qazilbash M, Hosing C, Jones RB, Popat UR, Nieto Y, Alousi A, Ciurea S, et al. Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013; 19:1059-64
3. Spyridonidis A, Labopin M, Schmid C, Volin L, Yakoub-Agha I, Stadler M, Milpied N, Socie G, Browne P, LenhoffS, Sanz MA, Aljurf M, Mohty M, et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia. 2012; 26:1211-7
4. Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, Dazzi F, Dreger P, Duarte R, Finke J, Garderet L, Greinix H, Holler E, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant. 2014; 49:168-73
5. Pui CH. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology Am Soc Hematol Educ Program. 2006:142-6
6. Chen S, Huang X, Zheng H, Geng S, Wu X, Yang L, Weng J, Du X and Li Y. The evolution of malignant and reactive gammadelta + T cell clones in a relapse T-ALL case after allogeneic stem cell transplantation. Mol Cancer. 2013; 12:73
7. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, McMillan AK, Tallman MS, Rowe JM, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007; 109:944-50
8. Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Tournilhac O, Buzyn A, Reman O, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007; 21:1907-14
9. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, Ferrando A, Fielding AK, Goldstone AH, Ketterling RP, Litzow MR, Luger SM, McMillan AK, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009; 114:5136-45
10. Pui CH and Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006; 354:166-78
11. Huo JS, Symons HJ, Robey N, Borowitz MJ, Schafer ES and Chen AR. Persistent Multiyear Control of Relapsed T-Cell Acute Lymphoblastic Leukemia With Successive Donor Lymphocyte Infusions: A Case Report. Pediatr Blood Cancer. 2016; 63:1279-82
12. Henig I and Zuckerman T. Hematopoietic stem cell transplantation-50 years of evolution and future perspectives. Rambam Maimonides Med J. 2014; 5:e0028
13. Czerw T, Labopin M, Schmid C, Cornelissen JJ, Chevallier P, Blaise D, Kuball J, Vigouroux S, Garban F, Lioure B, Fegueux N, Clement L, Sandstedt A, et al. High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reducedintensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia-an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Oncotarget. 2016; doi: 10.18632/oncotarget.8463
14. Zheng H, Wang X, Ma Y, Xu B, Chen S, Yang L, Wu X, Przybylski GK, Huang S and Ye T. The TCR repertoire and relative gene expression characteristics of T-ALL cases with biclonal malignant V1 and V2 T cells. DNA and cell biology. 2014; 33:49-56
15. Langerak AW, Wolvers-Tettero IL, van den Beemd MW, van Wering ER, Ludwig WD, Hahlen K, Necker A and van Dongen JJ. Immunophenotypic and immunogenotypic characteristics of TCRgammadelta+ T cell acute lymphoblastic leukemia. Leukemia. 1999; 13:206-14
16. Darlak KA, Wang Y, Li J-M, Harris WA, Giver CR, Huang C and Waller EK. Host bone marrow-derived IL-12 enhances donor T cell engraftment in a mouse model of bone marrow transplantation. J Hematol Oncol. 2014; 7:16
17. Shi L, Chen S, Zha X, Xu Y, Xu L, Yang L, Lu Y, Zhu K and Li Y. Enhancement of the TCR Expression, Polyclonal Expansion, and Activation of T Cells from Patients with Acute Myeloid Leukemia After IL-2, IL-7, and IL-12 Induction. DNA and cell biology. 2015; 34:481-8
18. Xiao H, Wang L-M, Luo Y, Lai X, Li C, Shi J, Tan Y, Fu S, Wang Y, Zhu N, He J, Zheng W, Yu X, et al. Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation. Oncotarget. 2016; 7:2696-708. doi: 10.18632/oncotarget.6259
19. Neumann M, Vosberg S, Schlee C, Heesch S, Schwartz S, Gokbuget N, Hoelzer D, Graf A, Krebs S, Bartram I, Blum H, Bruggemann M, Hecht J, et al. Mutational spectrum of adult T-ALL. Oncotarget. 2015; 6:2754-66. doi: 10.18632/oncotarget.2218
20. Karrman K, Castor A, Behrendtz M, Forestier E, Olsson L, Ehinger M, Biloglav A, Fioretos T, Paulsson K and Johansson B. Deep sequencing and SNP array analyses of pediatric T-cell acute lymphoblastic leukemia reveal NOTCH1 mutations in minor subclones and a high incidence of uniparental isodisomies affecting CDKN2A. J Hematol Oncol. 2015; 8:42
21. Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S and Lamb LS. Long term diseasefree survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 2007; 39:751-7
22. Meeh PF, King M, O'Brien RL, Muga S, Buckhalts P, Neuberg R and Lamb LS, Jr. Characterization of the gammadelta T cell response to acute leukemia. Cancer Immunol Immunother. 2006; 55:1072-80
23. Lamb LS Jr, Musk P, Ye Z, van Rhee F, Geier SS, Tong JJ, King KM and Henslee-Downey PJ. Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transplant. 2001; 27:601-6
24. Airoldi I, Bertaina A, Prigione I, Zorzoli A, Pagliara D, Cocco C, Meazza R, Loiacono F, Lucarelli B, Bernardo ME, Barbarito G, Pende D, Moretta A, et al. T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-+/CD19+ lymphocytes. Blood. 2015; 125:2349-58
25. Kobayashi H and Tanaka Y. T Cell Immunotherapy-A Review. Pharmaceuticals (Basel). 2015; 8:40-61
26. Wilhelm M, Smetak M, Schaefer-Eckart K, Kimmel B, Birkmann J, Einsele H and Kunzmann V. Successful adoptive transfer and in vivo expansion of haploidentical gammadelta T cells. J Transl Med. 2014; 12:45
27. Claret EJ, Alyea EP, Orsini E, Pickett CC, Collins H, Wang Y, Neuberg D, Soiffer RJ and Ritz J. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J Clin Invest. 1997; 100:855-66
28. Knies D, Klobuch S, Xue SA, Birtel M, Echchannaoui H, Yildiz O, Omokoko T, Guillaume P, Romero P, Stauss H, Sahin U, Herr W, Theobald M, et al. An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells. Oncotarget. 2016; doi: 10.18632/oncotarget.8385
29. Legut M, Cole DK and Sewell AK. The promise of T cells and the T cell receptor for cancer immunotherapy. Cell Mol Immunol. 2015; 12:656-68
30. Bartram I, Gökbuget N, Schlee C, Heesch S, Fransecky L, Schwartz S, Stuhlmann R, Schäfer-Eckhart K, Starck M and Reichle A. Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patients. Journal of hematology & oncology. 2014; 7:1-10
31. Ma S, Shi Y, Pang Y, Dong F, Cheng H, Hao S, Xu J, Zhu X, Yuan W and Cheng T. Notch1-induced T cell leukemia can be potentiated by microenvironmental cues in the spleen. J Hematol Oncol. 2014; 7:71
32. Huang X, Chen S, Shen Q, Yang L, Li B, Zhong L, Geng S, Du X and Li Y. Analysis of the expression pattern of the BCL11B gene and its relatives in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol. 2010; 3:44
33. Frost L, Goodeve A, Wilson G, Peake I, Barker H and Vora A. Clonal stability in late-relapsing childhood lymphoblastic leukaemia. Br J Haematol. 1997; 98:992-4
34. Wyld PJ and Lilleyman JS. Late relapse after presumed cure of childhood lymphoblastic leukaemia. Lancet. 1981; 2:86
35. Feldman F and Tan CV. Acute leukemia-relapse after prolonged remission. J Pediatr. 1970; 76:926-7
36. Roberto A, Castagna L, Zanon V, Bramanti S, Crocchiolo R, McLaren JE, GandolfiS, Tentorio P, Sarina B and Timofeeva I. Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. Blood. 2015; 125:2855-64
37. Xu L, Zhang Y, Luo G and Li Y. The roles of stem cell memory T cells in hematological malignancies. Journal of hematology & oncology. 2015; 8:1-5
38. Casorati G, De Libero G, Lanzavecchia A and Migone N. Molecular analysis of human gamma/delta+ clones from thymus and peripheral blood. J Exp Med. 1989; 170:1521-35
39. Triebel F and Hercend T. Subpopulations of human peripheral T gamma delta lymphocytes. Immunol Today. 1989; 10:186-8
40. Borst J, Wicherink A, Van Dongen JJ, De Vries E, Comans-Bitter WM, Wassenaar F and Van Den Elsen P. Non-random expression of T cell receptor gamma and delta variable gene segments in functional T lymphocyte clones from human peripheral blood. Eur J Immunol. 1989; 19:1559-68
41. Xu L, Lu Y, Lai J, Yu W, Zhang Y, Jin Z, Xu Y, Chen J, Zha X, Chen S, Yang L and Li Y. Characteristics of the TCR Vbeta repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations. Sci China Life Sci. 2015; 58:1276-81